NEDA-3 status including cortical lesions in the comparative evaluation of natalizumab versus fingolimod efficacy in multiple sclerosis.

Marco PuthenparampilChiara CazzolaSofia ZywickiLisa FederleErica StropparoMariagiulia AnglaniFrancesca RinaldiPaola PeriniPaolo Gallo

Published in: Therapeutic advances in neurological disorders (2018)

The incorporation of CLs in the NEDA-3 definition highlighted the higher efficacy of natalizumab versus fingolimod in suppressing disease activity in RMS patients.

Keyphrases

multiple sclerosis
disease activity
systemic lupus erythematosus
rheumatoid arthritis
white matter
end stage renal disease
rheumatoid arthritis patients
newly diagnosed
ejection fraction
ankylosing spondylitis
prognostic factors
signaling pathway